newwin
Luciann Nguyen
Settings
← Accounts
academic

Changhai Hospital

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Changhai Hospital

New trial — Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

New trialNCT04146298
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1_2 trial NCT04146298 posted by Changhai Hospital: "Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 258 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT04146298
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
phase 1 2
mol. elig.